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Effect of hepatitis C infection and renal transplantation on survival in
end-stage renal disease. Hepatitis C virus (HCV) infection is common
among patients with end-stage renal disease (ESRD). However, the effect
of HCV infection on survival among ESRD patients, and the impact of
renal transplantation on the course of HCV infection has not been
adequately defined. Sera from patients on the renal transplant waiting list
at the New England Organ Bank between November 1986 and June 1990
were tested for anti-HCV using a third generation ELISA. All anti-HCV
positive patients and a 1:1 ratio of randomly selected anti-HCV negative
patients comprised the study sample. Duration of follow-up was calculated
from the date of the first available serum specimen until death, loss to
follow-up or December 31, 1995, whichever occurred earlier. Multivariate
analysis of risk factors for mortality was performed using a Cox propor-
tional hazards model which included anti-HCV as a time-independent
(baseline) variable, transplantation as a time-dependent (follow-up) vari-
able, and independently significant baseline covariates. Anti-HCV was
detected in 287 (19%) of 1544 patients in whom sera were available, and
286 anti-HCV negative patients served as controls. Complete information
was available in 496 (87%) of these 573 patients. Median follow-up was 73
months (range 1 to 110 months), during which time 302 (61%) patients
underwent renal transplantation and 154 (31%) patients died. For anti-
HCV positive patients compared to anti-HCV negative patients, the
relative risk of death (and 95% confidence intervals) from all causes was
1.41 (1.01 to 1.97) and due to liver disease or infection was 2.39 (1.28 to
4.48). For patients who underwent transplantation compared to those who
remained on dialysis, the relative risk of death from all causes between 0
to 3 months, 3 to 6 months, seven months to four years, and after four
years was 4.75 (2.76 to 8.17), 1.76 (0.75 to 4.13), 0.31 (0.18 to 0.54) and
0.84 (0.51 to 1.37), respectively. There was no interaction between the
effect of anti-HCV status at baseline and subsequent transplantation (P 5
0.93), meaning that the association between treatment modality and
survival was similar among anti-HCV positive and negative patients, at all
intervals after transplantation. We conclude that HCV infection at the
time of referral for transplantation is associated with an increased risk of
death, irrespective of whether patients remain on dialysis or undergo
transplantation. Transplantation has a beneficial rather than adverse
effect on long-term survival in anti-HCV positive patients. Hence, anti-
HCV positive status alone is not a contraindication for renal transplanta-
tion.
Hepatitis C virus (HCV) infection is common among patients
with end-stage renal disease (ESRD)[1]. Among 27,086 patients
from dialysis centers participating in the National Surveillance of
Dialysis Associated Diseases in the United States conducted by
the Center for Disease Control and Prevention (CDC), the
prevalence of anti-HCV by ELISA2 was 8.1%, with a range of 0
to 51% among centers with at least 40 patients[2]. Likewise,
among renal transplant recipients, the prevalence of pre-trans-
plantation anti-HCV ranged from 11% to 49%[3–10]. The effect
of HCV infection on patient survival after renal transplantation
has been a subject of debate, with some, but not all studies finding
an increased risk of death among patients with pre-transplanta-
tion anti-HCV[3, 4, 7, 9, 10].
More importantly, the impact of renal transplantation (com-
pared to staying on dialysis) on the course of HCV infection has
not been adequately defined. Transplantation is associated with
improved long-term survival of patients with ESRD[11]. However,
transplantation can also worsen the course of some viral infec-
tions[12, 13]. Consequently, transplant physicians have been faced
with a dilemma regarding whether anti-HCV positive patients
with ESRD should be considered for renal transplantation. With
34,766 patients on the renal transplant waiting list in the U.S.
alone[14], the merits of allocating kidneys to anti-HCV positive
patients need to be addressed.
We compared the effects of anti-HCV status (positive vs.
negative) and treatment modality (dialysis vs. transplantation) on
long-term survival in a cohort of patients referred for renal
transplantation to centers served by the New England Organ
Bank (NEOB).
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METHODS
Patients
The study sample for this historical cohort study was drawn
from all 14 transplant centers in the six New England states served
by the NEOB. All patients on the renal transplant waiting list
between November 1986 and January 1987 (“prevalent” popula-
tion) as well as those referred for renal transplantation between
February 1987 and June 1990 (“incident” population) were iden-
tified from the Tissue Typing Laboratory records of the NEOB.
June 1990 was used as the cut-off date because the introduction of
anti-HCV testing subsequent to that date could influence referral
for renal transplantation. For prevalent patients, the first serum
sample available during the period between November 1986 and
January 1987 was retrieved for anti-HCV testing. For incident
patients, the first serum sample available within six months of
referral for transplantation was retrieved for anti-HCV testing.
The anti-HCV positive cohort comprised all anti-HCV positive
patients. A cohort of anti-HCV negative patients was randomly
selected from the prevalent and incident patients at each center in
a 1:1 ratio with the anti-HCV positive patients. Recipients of
living-related and cadaver donors were included. Recipients from
anti-HCV positive donors were not included
Test for anti-hepatitis C virus antibody
Serum samples, stored at 270°C were retrieved from the
NEOB and the Tissue Typing Laboratories at Brigham and
Women’s Hospital, Massachusetts General Hospital, and Maine
Medical Center. Anti-HCV testing was performed using the third
generation ELISA (Orthoy HCV ELISA 3.0 Test System; Ortho
Diagnostics System, Raritan, NJ, USA) which detects antibodies
to recombinant HCV antigens (c22, c200, NS5) derived from the
nonstructural (NS3, NS4, NS5) and core regions of the viral
genome. The assay was performed by Ortho Diagnostics System.
Clinical information
Clinical data were collected from the NEOB records, United
Network for Organ Sharing Computer Services, ESRD Networks
of New England and New York, databases of the Tissue Typing
Laboratories of Brigham and Women’s Hospital, Massachusetts
General Hospital, and Maine Medical Center, and hospital,
transplant office and dialysis unit medical records at the partici-
pating centers. Enrollment into the study was defined as the date
of the first available serum specimen. Clinical information col-
lected at the time of enrollment included age at onset of renal
replacement therapy, gender, race, cause of ESRD, presence of
diabetes mellitus, year of initiation of renal replacement therapy
(dialysis or transplantation), date of listing for renal transplanta-
tion at the NEOB, dialysis modality, history of liver disease and
non-A, non-B hepatitis (NANBH), number of blood transfusions,
number of previous transplants, blood group, panel reactive
antibody (PRA) assay, hepatitis B surface antigen (HBsAg),
antibody to hepatitis B surface antigen (anti-HBs), antibody to
hepatitis B core antigen (anti-HBc), antibody to cytomegalovirus
(anti-CMV), and serum ALT and albumin levels. Serum ALT was
considered elevated if it was greater than two and a half times the
upper limit of normal. Duration of follow-up was calculated from
the enrollment date until death, loss to follow-up or December 31,
1995, whichever occurred earlier.
Statistical analysis
Clinical characteristics were compared between the prevalent
and incident cohorts using two-sample tests with two-tailed P
values. For continuous variables (age, duration of renal replace-
ment therapy and serum albumin level), Student t-tests were used.
For all other variables, x2 tests were used.
Univariate and multivariate analysis of risk factors for mortality
was performed using a Cox proportional hazards model. Since this
was an intention-to-treat analysis, patients who were removed
from the waiting list due to illness or complications were analyzed
as if they remained on the waiting list from the date of enrollment
until end of follow-up. The date of referral for transplantation
could be ascertained for the incident group, but not for the
prevalent group. Therefore, patient survival was computed from
onset of treatment for ESRD. Patients did not contribute to the
part of the survival curve during the interval between onset of
ESRD and enrollment into the study. Individual patient experi-
ence was therefore truncated on the left [15] and censored on the
right of the survival curve. Most patients contributed information
to the middle part of the survival curve.
The independent variables, anti-HCV status and transplanta-
tion, were included in all multivariate models. Anti-HCV status
was treated as a time-independent (baseline) variable. Transplan-
tation was treated as a time-dependent (follow-up) variable whose
status changed upon transplantation. Almost all patients contrib-
uted information to the dialysis group survival curve, but only
those who underwent transplantation contributed information to
the transplant group survival curve. Patients who underwent
transplantation continued to contribute to the transplant curve,
irrespective of subsequent graft loss. Several forms of the trans-
plantation variable were examined to determine if its effect
changed during follow-up. These included both the simple pres-
ence/absence of transplantation as well as linear terms for inter-
val, since transplantation and step functions that allowed the
effect to change arbitrarily from year to year and from quarter to
quarter within the first year after transplantation. Time-indepen-
dent (baseline) covariates a priori considered for inclusion were
age at onset of renal replacement therapy, gender, race (white vs.
not white), diabetes mellitus and number of previous transplants.
Age and number of previous transplants were treated as linear
effects after checking that this formulation was appropriate. In
addition, variables listed in Table 2 were included if significant.
Two factor interactions between anti-HCV status, transplantation
and baseline covariates were also tested.
Variable selection in the multivariate model proceeded as
follows using x2 likelihood ratio tests with a nominal P value of
0.05 to compare models. (1) All five a priori selected baseline
covariates, other significant covariates and anti-HCV status were
included in a series of models with different parameterizations of
the transplantation effect to determine its proper shape. (2) Next,
backward stepwise elimination was used to retain only the signif-
icant baseline covariates in the final model along with anti-HCV
status and transplantation. (3) All two-factor interactions were
then examined by comparing the main effects model from step 2
against models with one interaction term added. Interactions were
not retained if P . 0.05.
Residual diagnostics were performed on these final models.
The proportional hazards assumption was checked by computing
the Schoenfeld residuals and checking that they exhibited no
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significant correlation with the ranked failure times. A graphical
check was also made by plotting the residuals against time and
fitting a smooth curve with 95% confidence bands. Potential
influence points were checked by looking at the score residuals.
Linearity of covariates was assessed by modeling the binary
outcome in a Poisson generalized additive regression as a function
of all the terms in the final survival model using a smoothing
spline representation of the continuous variables and an offset
term that equaled the difference between the log of the predicted
values and the linear predictor from the Cox model. We added
0.01 to those values predicted to equal zero in order to be able to
calculate the log.
The model for specific causes of death (liver disease or infec-
tion) used the same variables as in the final all-cause mortality
model. Because patients were not dialyzed at the transplant
centers and patients using the same dialysis unit could have been
referred to different transplant centers, we did not include
transplant center as a stratification variable in the main analysis.
However, we did check that including transplantation center as a
stratification factor did not substantially change the results.
Calculations were performed using SAS/Stat version 6.12 (SAS
Institute Inc., Cary, NC, USA), except for residual diagnostics
which were performed using S-Plus version 3.3 for Windows
(StatSci, a division of MathSoft Inc., Seattle, WA, USA).
RESULTS
Prevalence of anti-hepatitis C virus antibody and description of
study groups
Sera were available for anti-HCV testing in 394 (60%) of 655
patients in the prevalent population, 1150 (44%) of 2588 patients
in the incident population and 1544 (48%) of 3243 patients in the
total population (Table 1). One hundred and thirty-nine (35%) of
394 patients in the prevalent population tested positive for
anti-HCV compared to 148 (13%) of 1150 patients in the incident
population (P 5 0.001). Thus, overall 287 (19%) of 1544 patients
tested positive for anti-HCV. Two hundred and eighty-six ran-
domly selected anti-HCV negative patients served as controls.
Thus, a total of 573 patients (261 prevalent and 312 incident
patients) were selected for the study.
Complete information on baseline covariates, subsequent trans-
plantation and mortality was available in 217 (84%) of 261
prevalent patients, 279 (90%) of 312 incident patients and 496
(87%) of 573 patients overall. This constituted the final study
sample. Median follow-up was 84 months (range 1 to 110) in the
prevalent patients, 70 months (1 to 110) in the incident patients
and 73 months (1 to 110 months) overall.
Prevalent and incident cohorts at baseline
As shown in Table 2, the prevalent sample had a higher
proportion of patients with ESRD due to glomerular disease,
history of previous transplantation, history of blood transfusions,
high titers of panel reactive antibodies and history of liver disease,
and a lower proportion of patients with diabetes mellitus. Since
anti-HCV negative controls were selected separately for the
prevalent and incident samples, the two samples were combined
for further analyses.
Anti-hepatitis C virus antibody status, transplantation and
death
Among the 496 patients in the final study sample, 302 (61%)
patients underwent renal transplantation and 154 (31%) patients
died (Table 3). The cause of death was ascertained in 133 (86%)
of 154 patients who died, and was liver disease in 12 (9%) and
infection in 38 (29%). Comparing anti-HCV positive to anti-HCV
negative patients, median follow-up was 72 versus 73 months,
respectively. The proportion of patients who underwent trans-
plantation was 50% versus 70%, respectively. The all-cause mor-
tality was 38% versus 26%, respectively. Liver disease or infection
was the cause of death in 43% versus 30% of deaths, respectively.
Figure 1 shows the survival since start of renal replacement
therapy among anti-HCV positive and negative patients (Fig. 1A),
and the contribution of patients to the survival curve according to
their anti-HCV status and whether they underwent transplanta-
tion (Fig. 1 B-E). The impact of the left truncation is apparent in
Figure 1. Anti-HCV negative patients (Fig. 1 B, C) contributed
more to the early part of the survival curve than did anti-HCV
positive patients (Fig. 1 D, E).
Univariate model. The univariate model showed that transplan-
tation had a non-linear effect that depended on the time since
transplant. Compared to patients who remained on dialysis,
mortality was higher for transplanted patients in the first six
months following transplantation, but was lower thereafter. We
modeled this as a step function (Table 4) in which the relative
risks of death (and 95% confidence intervals) were 4.28 (2.51 to
7.30) in the first three months, 1.51 (0.64 to 3.51) in the next three
months, 0.28 (0.15 to 0.49) from seven months to four years, and
0.80 (0.49 to 1.30) after four years. Anti-HCV positive status was
associated with a 1.35-fold (0.97 to 1.89) higher risk of death.
Table 1. Characteristics of the study samplea
Patient
population Sera availabled
Anti-HCV
positive
Anti-HCV
negative
controls Total
Complete clinical
data availablee
Follow-up
monthse
Prevalentb 394/655 (60%) 139/394 (35%) 122 261 217/261 (84%) 84 (1–110)
Incidentc 1150/2588 (44%) 148/1150 (13%) 164 312 279/312 (90%) 70 (1–110)
Overall 1544/3243 (48%) 287/1544 (19%) 286 573 496/573 (87%) 73 (1–110)
a Data for continuous variables are presented as median (range) and for discrete variables as fraction positive (percent).
b Patients on the renal transplant waiting list between November, 1986 and January, 1987.
c Patients referred for renal transplantation between February 1987 and June 1990.
d For prevalent patients, the first serum sample available during the period between November 1986 and January 1987, and for incident patients, the
first serum sample available within the first six months of referral for transplantation.
e Baseline covariates and follow-up until death, loss to follow-up or December 31, 1995, whichever occurred earlier.
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Examination of the baseline covariates showed that each addi-
tional year of age at onset of renal replacement therapy and the
diagnosis of diabetes conferred a relative risk of death of 1.05
(1.03 to 1.06) and 1.99 (1.35 to 2.95), respectively. Gender, race
and number of previous transplants were not significant predictors
of mortality, nor were any of the other variables listed in Table 2.
Final multivariate model. None of the interactions terms tested
were significant and hence none were included in the final model.
Therefore, the final multivariate model consisted of anti-HCV
status at baseline, transplantation, age and diabetes (Table 4).
Comparing anti-HCV positive patients to anti-HCV negative
patients, the relative risk of death from all causes was 1.41 (1.01 to
1.97) and the relative risk of death due to liver disease or infection
was 2.39 (1.28 to 4.48). Comparing patients who underwent
transplantation to those who remained on dialysis, the relative risk
of death from all causes between 0 to 3 months, 3 to 6 months,
seven months-four years and after four years was 4.75 (2.76 to
8.17), 1.76 (0.75 to 4.13), 0.31 (0.18 to 0.54) and 0.84 (0.51 to 1.37),
respectively. There was no interaction between the effect of
anti-HCV status at baseline and subsequent transplantation (P 5
0.93), meaning that the association of these two variables with
survival was independent of each other. The absence of interac-
tion is shown in Figure 2, where the relative risk of death among
patients who underwent transplantation compared to those who
remained on dialysis was similar among anti-HCV positive and
negative patients, at all intervals after transplantation. For each
additional year of age at onset of renal replacement therapy and
the diagnosis of diabetes the relative risk of death was 1.05 (1.03
to 1.06) and 1.75 (1.19 to 2.59), respectively. Inclusion of trans-
plant center as a stratification variable in the regression model did
not affect the regression coefficients significantly. The point
estimate for the relative risk of death for anti-HCV was 1.36 and
for transplantation was 4.68, 1.64, 0.34 and 0.93, respectively
between 0 to 3 months, 3 to 6 months, 7 months to 4 years and
after 4 years. Residual diagnostics showed no evidence of nonlin-
earity, lack of proportional hazards or the presence of any
influence points.
DISCUSSION
This study demonstrates that among patients referred for renal
transplantation to the 14 transplant centers served by the New
England Organ Bank between 1986 and 1990, the presence of
anti-HCV was associated with a higher risk of death. Receiving a
transplant was associated with a higher risk of death within the
first six months after surgery, but a lower risk of death thereafter.
Most important, these two associations were independent, indi-
cating that the presence of anti-HCV is associated with a poor
prognosis, irrespective of whether the patient receives a transplant
or remains on dialysis, and that the effect of transplantation was
similar in anti-HCV positive and negative patients referred for
transplantation. These findings have important implications for
policies in dialysis units and transplant programs.
In designing this study, two potential causes of bias in patient
selection had to be taken into account. First, physicians’ decisions
to refer patients for transplantation could have been influenced by
their knowledge of the patients’ anti-HCV status. To avoid this
bias, we only included patients who were referred for renal
transplantation prior to the advent of anti-HCV testing in June
1990. Second, physicians tend to refer healthier patients for
transplantation, leaving sicker patients on dialysis. Indeed, crude
mortality rates among dialysis patients are twice as high in
patients who are not referred for renal transplantation compared
to patients who are referred for transplantation [11]. To avoid this
bias, we only included patients who completed the requisite
pre-transplantation medical evaluation process, were deemed
suitable transplant candidates by their treating physician, and
were placed on the waiting list. Nonetheless, the possibility cannot
be excluded that medical contraindications for renal transplanta-
tion arising after listing may have precluded renal transplantation
in some patients, thus contributing to the increased risk of death
in the dialysis group.
Using ELISA3, we found a 19% prevalence of anti-HCV
among dialysis patients referred for renal transplantation. As
discussed earlier, these results are similar to those in other dialysis
Table 2. Clinical characteristics of prevalent and incident patients on
the renal transplantation waiting lista
Prevalent
N 5 217b
Incident
N 5 279c Pd
Age years 40 (9–68) 39 (1–76) 0.39
Gender % male 112/217 (52%) 164/279 (59%) 0.11
Race % Caucasian 157/217 (72%) 216/279 (77%) 0.10
Diabetes mellitus 27/217 (12%) 67/279 (24%) 0.001
Time since initiation of
renal replacement
therapy months
73 (0–245) 15 (0–279) ,0.001
Dialysis modality %
hemodialysis
188/212 (87%) 223/267 (84%) 0.11
Number of previous
transplants
0.001
0 103/217 (47%) 202/279 (72%)
1 85/217 (39%) 60/279 (21%)
2 25/217 (12%) 12/279 (4%)
3 4/217 (2%) 5/279 (2%)
Number of transfusions 0.001
0 4/129 (3%) 28/157 (18%)
1–5 26/129 (20%) 45/157 (29%)
6–10 21/129 (16%) 28/157 (18%)
.10 78/129 (61%) 56/157 (35%)
Blood group 0.40
A 64/192 (33%) 90/236 (38%)
B 17/192 (9%) 28/236 (12%)
AB 7/192 (4%) 6/236 (3%)
0 104/192 (54%) 112/236 (47%)
Panel reactive antibody % 0.01
,10 11/48 (23%) 62/130 (48%)
10–50 17/48 (35%) 28/130 (22%)
50–90 10/48 (21%) 25/130 (19%)
.90 10/48 (21%) 15/130 (11%)
Hepatitis B serology
HBsAg 3/160 (2%) 5/219 (2%) 0.79
Anti-HBs 27/98 (28%) 42/159 (26%) 0.84
Anti-HBc 6/27 (22%) 5/36 (14%) 0.39
Anti-CMV 42/72 (58%) 99/179 (55%) 0.68
History of liver disease 50/201 (25%) 47/271 (17%) 0.05
Elevated ALTe 7/122 (6%) 11/159 (7%) 0.81
Albumin g/dl 3.8 (2.2–5.1) 3.9 (2.0–5.1) 0.24
a Data for continuous variables are presented as median (range) and for
discrete variables as fraction positive (percent).
b Patients on the renal transplant waiting list between November, 1986
and January, 1987.
c Patients referred for renal transplantation between February, 1987
and June, 1990.
d Pearson’s chi-square test for discrete variables and Student’s t-test for
continuous data.
e Greater than two and a half times the upper limit of normal.
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centers in the U.S. [2]. The 35% prevalence of anti-HCV among
patients on the renal transplant waiting list in 1986 (prevalent
population) was significantly higher than the 13% prevalence
among patients referred for renal transplantation between 1987
and 1990 (incident population). The higher prevalence of anti-
HCV in the prevalent population was probably due to the fact that
this group had a higher proportion of highly sensitized patients,
who had been on the waiting list longer and had received multiple
blood transfusions or previous kidney transplants. These factors
are all associated with a higher risk of acquiring HCV infection.
The lower prevalence of anti-HCV among patients referred for
renal transplantation after 1987 may also reflect a declining trend
in the incidence and prevalence of non-A, non-B hepatitis
(NANBH) that was observed even prior to the discovery of HCV
[2]. This decline was probably the result of exclusion of blood
products that tested positive for surrogate markers of NANBH
such as elevated ALT and anti-HBc, and the implementation of
strategies to reduce transmission of blood-borne infections in
dialysis units [16, 17]. Since the discovery of HCV, the advent of
testing of blood products for anti-HCV and the implementation of
even more rigorous infection-control measures have led to a
further decline in the incidence and prevalence of HCV infection.
Overall, the incidence of NANBH among dialysis patients in the
U.S. declined from 1.7% in 1982 to 0.5% in 1992 [2].
Among patients referred for renal transplantation, the presence
of HCV infection was associated with a 1.41-fold (1.01- to
1.97-fold) increased risk of death. These findings confirm previous
studies from our group [3] and others [10] showing that pre-
transplantation HCV infection is associated with an increased
mortality after transplantation. In a randomly selected cohort of
103 patients who received kidneys from anti-HCV negative do-
nors at NEOB transplant centers between 1986 and 1990, recip-
ients with pre-transplantation anti-HCV had a 3.3-fold higher risk
of death than recipients without pre-transplantation anti-HCV
[3]. The lower relative risk of death for anti-HCV positive patients
in the current study (1.4) compared to our previous results (3.3)
appears to be the result of a higher mortality among anti-HCV
negative patients in the current study (26%) compared to our
previous study (15%). One possible explanation for this finding is
that some of the anti-HCV negative patients in the current study
may have acquired the HCV infection during the interval between
referral for transplantation and receiving the transplant. Evalua-
tion of this hypothesis would require testing of serial serum
specimens.
In contrast, others have not detected significant differences in
patient survival between transplant recipients with and without
pre-transplantation anti-HCV [4, 7, 9]. The different results
among studies could be due to factors such as differences in
selection of patients and more importantly, the limited duration
and completeness of follow-up in studies that did not find an
increased risk of death among anti-HCV positive patients. Indeed,
the progression of liver disease due to HCV and its attendant
complications are related to the duration of infection. The interval
between the initial presentation of post-transfusion NANBH and
the onset of chronic hepatitis, cirrhosis and hepatocellular carci-
noma is 10, 21 and 29 years, respectively [18]. We rigorously
tracked post-transplantation outcomes in all patients. Similar
results were not reported in the studies by others. In principle, a
less complete follow-up could possibly fail to identify patients who
died. Alternatively, this difference might reflect differences in the
severity of HCV infection. In our study, 40% of anti-HCV positive
patients had a history of liver disease at the time of referral for
transplantation (data not shown). Indeed, pre-transplantation
liver disease is associated with an increased risk of death [3]. In
principle, a lower prevalence of pre-transplantation liver disease
among anti-HCV positive recipients in other studies would be
reflected in a higher post-transplantation survival! More accurate
assessment of the severity of pre-transplantation liver disease, for
example liver biopsy, would be necessary to address this question.
Indeed, pre-transplantation liver histology has been shown to be a
good predictor of adverse post-transplantation outcomes [19].
Finally, the virulence of the virus differs between strains of the
virus, and the differences in the distribution of various strains
could possibly explain differences in the results obtained from
different geographical regions.
Our finding of an increased mortality among anti-HCV positive
ESRD patients referred for renal transplantation is at variance
with outcomes in some studies on non-ESRD patients with
post-transfusion NANBH. Seeff and colleagues studied long-term
outcomes in five studies of transfusion-associated hepatitis that
began between 1967 and 1980 [20]. After an average of 18 years of
follow-up, the overall mortality was 51% among patients with
post-transfusion NANBH as well as in two control groups of
patients who had received transfusions but had not developed
NANBH. Since HCV accounts for more than 60% of NANBH,
these results suggest that post-transfusion HCV infection did not
adversely affect survival, at least for up to two decades. Possibly
the greater adverse effect of HCV infection in patients with
ESRD is the result of immune dysfunction. Indeed, patients with
ESRD are afflicted by several defects in cellular and humoral
mechanisms including abnormal chemotaxis, adherence, phagocy-
tosis and release of mediators by granulocytes, impaired function
Table 3. Subsequent transplantation and mortality among anti-HCV positive and negative patients referred for renal transplantationa
Anti-HCVb
Follow-up
months
Subsequent
transplantationc
All-cause
mortalityc
Cause of
death
ascertained
Deaths from
liver
diseased
Deaths from
infectiond
Deaths from
liver disease
or infectiond
Positive (N 5 223) 72 (1–108) 111 (50%) 84 (38%) 76 (90%) 11 (14%) 22 (29%) 33 (43%)
Negative (N 5 273) 73 (1–110) 191 (70%) 70 (26%) 57 (81%) 1 (2%) 16 (28%) 17 (30%)
Overall (N 5 496) 73 (1–110) 302 (61%) 154 (31%) 133 (86%) 12 (9%) 38 (29%) 50 (38%)
a Data for continuous variables are presented as median (range) and for discrete variables as fraction positive (percent).
b In the first serum sample available during the period between November 1986 and January 1987 (prevalent patients) or the first serum sample
available within the first six months of referral for transplantation (incident patients).
c Follow-up until death, loss to follow-up or December 31, 1995, whichever occurred earlier.
d Among those in whom the cause of death was ascertained.
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of macrophage Fc receptors [21], and defective T- lymphocyte
function [22].
Patients with advanced liver disease in general and cirrhosis in
particular have multiple immunological defects including reduced
cell-mediated immunity [23, 24]; reduced neutrophil phagocytic
and killing ability [25] and impaired macrophage Fc receptor
function [26]. The immune dysfunction due to liver disease is
likely to be exacerbated by the immune dysfunction of uremia and
consequently increase the susceptibility to lethal infections.
Therefore, we also included death due to liver disease or infection
as an end-point. In the current study, we observed a 2.4-fold
higher risk of death due to liver disease or infection among
anti-HCV positive patients referred for renal transplantation. An
increased risk of death due to liver disease among anti-HCV
positive patients has also been observed in non-ESRD patients.
Among patients with post-transfusion NANBH, Seeff and col-
league observed that the frequency of death due to liver disease
was 3.3% compared to 1.1% and 2.0% in two control cohorts
without NANBH [20]. Deaths due to infection were not reported
in this study.
The higher mortality in ESRD patients with anti-HCV under-
scores the importance in preventing HCV infection in these
patients. These patients are at risk of acquiring HCV infection
from blood product transfusions or from other patients in hemo-
dialysis units. The advent of screening of blood products for
anti-HCV in 1990 has virtually eliminated the transmission of
HCV infection by blood product transfusions[27]. Nonetheless,
factors responsible for nosocomial transmission within dialysis
Fig. 1. Survival among anti-HCV negative and positive patients referred for renal transplantation. (A) The unadjusted actuarial survival from the time
of first initiation of renal replacement therapy (dialysis or transplantation) until death, loss to follow-up or December 31, 1995, whichever occurred first.
Symbols are: (E) anti-HCV negative; (f) anti-HCV positive. (B through E) The number of anti-HCV negative and positive patients contributing to
different parts of the survival curve as either dialysis or transplant patients. Anti-HCV negative patients (B, transplant; C, dialysis) contributed more
to the early part of the survival curve than did anti-HCV positive patients (D, transplant; E, dialysis). A higher proportion of anti-HCV negative patients
(B, C) underwent transplantation than did anti-HCV positive patients (D, E).
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units are not well understood[1]. We recommend continuing study
of methods for control of HCV infection in dialysis units.
This study also demonstrates a long-term beneficial effect of
transplantation on survival of patients with ESRD. We observed
an initially higher risk of death (relative risk of 4.75 and 1.76
between 0 to 3 months and 3 to 6 months, respectively), but a
lower risk thereafter (0.31 between 7 months and 4 years, and 0.84
after 4 years). These findings are similar to those reported by Port
and colleagues using a similar study design [11]. Compared to
wait-listed dialysis patients, Port and colleagues observed a higher
relative risk of death in the first month after cadaveric renal
transplant (relative risk of 2.43), but a lower risk thereafter
(relative risk 0.96 between 1 to 12 months and 0.36 after 12
months). The absence of a significant interaction between anti-
HCV status and transplantation in our study indicates that the
effect of transplantation on survival was similar in anti-HCV
positive and negative patients (Fig. 2). These findings are consis-
tent with those of a recent study by Knoll and colleagues who
compared clinical outcomes among anti-HCV positive patients
referred for renal transplantation [28]. They found that patient
survival was significantly higher among the 33 patients who
underwent transplantation compared to the 25 patients who
remained on dialysis.
For several reasons, it has been assumed that the immunosup-
pression regimens used for renal transplantation may worsen the
course of HCV infection in ESRD. First, a higher prevalence of
chronic liver disease, overall mortality and death due to liver
disease has been reported among HBsAg positive patients who
underwent renal transplantation compared to those who re-
mained on dialysis [12, 29]. Second, among patients with HIV
infection, the acquired immunodeficiency syndrome (AIDS) de-
velops 1.5 to 2 years after infection in immunosuppressed trans-
plant recipients, compared to 7 to 8 years after infection in normal
hosts [13]. Third, among anti-HCV positive transplant recipients,
liver disease is seen more often among those who receive anti-
lymphocyte preparations such as antilymphocyte globulin, anti-
thymocyte globulin or OKT3 than those who do not [30, 31].
Fourth, among patients with HCV infection at the time of
transplantation, we have previously reported a median 6.6-fold
increase in HCV RNA titers after transplantation [3]. Finally, in
patients with primary hypogammaglobulinemia, HCV infection
appears to have an accelerated course. In one study [32], 73%
developed chronic active hepatitis and/or cirrhosis within a de-
cade after acquiring HCV infection. Overall, these observations
support the hypothesis that immunosuppressed patients are more
likely to develop adverse consequences of viral infections. Conse-
quently, transplant physicians have been reluctant to offer anti-
HCV positive ESRD patients the choice of renal transplantation.
Nonetheless, we found that the association between transplanta-
tion and survival was no different between anti-HCV positive and
negative patients. Thus, the possible detrimental effect of trans-
plantation on the course of HCV infection does not appear to
outweigh its long-term beneficial effect on survival in ESRD.
Hence, our results do not support withholding renal transplanta-
tion solely on the basis of a positive anti-HCV test.
In conclusion, HCV infection at the time of transplantation is
Fig. 2. Relative risk of death for transplantation versus dialysis among
anti-HCV negative (E) and positive (f) patients referred for renal
transplantation. The relative risk of death (and 95% confidence intervals)
for different time intervals after transplantation are adjusted for age and
the presence of diabetes. The relative risk of death for transplantation
versus dialysis was similar for anti-HCV positive and negative patients at
all intervals after transplantation.
Table 4. Relative risk of death among patients referred for renal transplantationa
Risk factor
Relative risk of death (95% confidence intervals)
Univariate model
all-cause mortality
Final multivariate model
All cause mortality
Mortality due to liver
disease or infection
Anti-HCV positive (vs. negative)b 1.35 (0.97–1.89) 1.41 (1.01–1.97) 2.39 (1.28–4.48)
Transplantation (vs. dialysis) Overall P , 0.0001 Overall P , 0.0001 Overall P , 0.0001
0–3 months post-transplantation 4.28 (2.51–7.30) 4.75 (2.76–8.17) 11.44 (5.33–24.55)
4–6 months post-transplantation 1.51 (0.64–3.51) 1.76 (0.75–4.13) 4.10 (1.33–12.67)
7–47 months post-transplantation 0.28 (0.15–0.49) 0.31 (0.18–0.54) 0.37 (0.13–1.08)
.48 months post-transplantation 0.80 (0.49–1.30) 0.84 (0.51–1.37) 0.67 (0.22–2.00)
Age at onset of ESRD (per year) 1.05 (1.03–1.06) 1.05 (1.03–1.06) 1.05 (1.03–1.08)
Diabetes mellitus (vs. non-diabetics) 1.99 (1.35–2.95) 1.75 (1.19–2.59) 1.15 (0.55–2.40)
Number of previous transplants 1.02 (0.79–1.31)
Female gender (vs. male) 0.79 (0.57–1.09)
Non-white race (vs. white) 1.28 (0.90–1.81)
a Patients on the renal transplant waiting list between November 1986 and January 1987 (prevalent patients), and those referred for renal
transplantation between February 1987 and June 1990 (incident patients).
b In the first serum sample available during the period between November 1986 and January 1987 (prevalent patients) or the first serum sample
available within the first six months of referral for transplantation (incident patients).
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associated with an increased risk of death, irrespective of whether
patients remain on dialysis or undergo transplantation. These
results emphasize the importance of measures to prevent noso-
comial transmission of HCV in dialysis units. In the absence of a
prospective randomized trial, definitive conclusions cannot be
drawn regarding the risk of death among anti-HCV positive
ESRD patients treated by transplantation compared to dialysis.
Our study suggests that transplantation has a beneficial rather
than adverse effect on long-term survival in anti-HCV positive
patients. Hence, anti-HCV positive status alone is not a contra-
indication for renal transplantation, and anti-HCV positive ESRD
patients should be allowed to make an informed choice between
dialysis or transplantation.
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